Equity · Healthcare
PYXS
NASDAQPyxis Oncology (PYXS)
The line runs 3 USD on 24 August through 3.27 USD on 10 September, on a scale from 2.5 to 4.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 390.5M USD
- Revenue, year to Dec 2025
- 13.9M USD
- EPS, diluted, year to Dec 2025
- −1.28 USD
- 52-week range
- 1.04 USD – 5.34 USD
- Avg volume
- 88.7K
as of Sep 10, 2026
Have Pyxis Oncology (PYXS) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Pyxis Oncology insiders reported 1 open-market purchase and no sales (SEC Form 4).
Form 4, 90 days to 22 Nov 2026, newest reported trade 1 Oct 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Oct 2026 | GordonMD Global Investments LP10% Owner | Buy | 5,517,000 | — |
Which funds hold Pyxis Oncology (PYXS)?
7 of the 45 institutional funds we track reported a Pyxis Oncology position for the quarter ended 30 Sep 2026 — a combined 6.3M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Added | 831,700 | 1.9M USD | +256.9% |
| Marshall Wace | Held (±25%) | 760,093 | 1.8M USD | −8.5% |
| Soros Fund Management | New position | 476,113 | 1.1M USD | |
| Renaissance Technologies | Trimmed | 367,780 | 857K USD | −52.4% |
| Citadel Advisors | Added | 198,431 | 462K USD | +319.4% |
| Two Sigma Investments | Trimmed | 46,700 | 109K USD | −44.4% |
| Balyasny Asset Management | New position | 19,361 | 45K USD | |
| Point72 Asset Management | Exited |
What has been filed or recorded for Pyxis Oncology (PYXS)?
The filings we hold for Pyxis Oncology, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 29 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,000 shares | 6K USD notional · 0.003% of shares out |
| 22 Oct 2026 | Fails to deliver | Shares failed to deliver | 14,091 shares | 25K USD notional · 0.012% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.24 USD | |
| 30 Sep 2026 | Financials | Total assets | 76.8M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 41.3M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.40 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.37 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.28 USD | Revenue $14M |
| 31 Dec 2025 | Financials | Revenue | 13.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −79.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.28 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.35 USD | Revenue $3M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.30 USD | Revenue $3M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.35 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.32 USD | Revenue $16M |
What do people ask about Pyxis Oncology (PYXS)?
What did Pyxis Oncology shares close at?3.27
Pyxis Oncology closed at 3.27 USD on 10 Sep 2026, up 8.83% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Pyxis Oncology’s market cap?390.5M
Pyxis Oncology is worth 390.5M USD by market value as of 10 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is Pyxis Oncology’s revenue?13.9M
Pyxis Oncology reported revenue of 13.9M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Pyxis Oncology insiders bought or sold shares recently?1 purchase
In the 90 days to 22 Nov 2026, Pyxis Oncology insiders reported 1 open-market purchase and no sales (SEC Form 4). See Insiders
Which funds own Pyxis Oncology?7 of 45
7 of the 45 funds we track reported a Pyxis Oncology position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Marshall Wace and Soros Fund Management. See Funds
When did Pyxis Oncology last report earnings?−0.24
Pyxis Oncology last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.24 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words